Cargando…
Efficacy and safety of erenumab in women with a history of menstrual migraine
BACKGROUND: We performed a post hoc, subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled study of erenumab for prevention of episodic migraine (STRIVE) to determine the efficacy and safety of erenumab in women with self-reported menstrual migraine. METHODS: Patients received...
Autores principales: | Pavlovic, Jelena M., Paemeleire, Koen, Göbel, Hartmut, Bonner, Jo, Rapoport, Alan, Kagan, Risa, Zhang, Feng, Picard, Hernan, Mikol, Daniel D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398400/ https://www.ncbi.nlm.nih.gov/pubmed/32746775 http://dx.doi.org/10.1186/s10194-020-01167-6 |
Ejemplares similares
-
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020) -
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020) -
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020) -
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021) -
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)